PTGX
Protagonist Therapeutics Inc
NASDAQ: PTGX · HEALTHCARE · BIOTECHNOLOGY
$103.50
-5.26% today
Updated 2026-06-05
Market cap
$6.10B
P/E ratio
—
P/S ratio
85.51x
EPS (TTM)
$-1.81
Dividend yield
—
52W range
$49 – $108
Volume
0.6M
Protagonist Therapeutics Inc (PTGX) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed PTGX price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$103.50
Today
Analyst consensus
$115.21
+11.31% · 12M
2030 Base
$508.08
+390.90% future
NPV today
$267.83
@ 15% WACC
16 analysts:
14 Buy1 Hold1 Sell
Management guidance
Management has not provided specific multi-year revenue targets in public guidance. However, CEO Dinesh Patel has emphasized the company's transition to a milestone and royalty-based business model anchored by partnerships with Takeda and Johnson & Johnson. The company reported Q1 2026 revenue of $56.37M (TTM $74.06M) and received a $50M FDA milestone for ICOTYDE approval plus $200M from rusfertide collaboration restructuring, signaling material near-term cash inflows beyond organic product revenue.
Sources: Management guidance, analyst consensus, sector analysismedium confidence
PTGX · Protagonist Therapeutics Inc · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$873.16
NPV today: $460.28
Base case (2030)
$508.08
NPV today: $267.83
Bull case (2030)
$2,881.12
NPV today: $1,518.75
WallStSmart.com
PTGX financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $0.0B | $0.2B | $0.5B | $1.0B | $1.5B | $2.0B |
| Revenue growth | -89.4% | 1030.0% | -64.4% | 72.9% | 50.0% | 29.2% |
| Net margin | — | 135.7% | -10.4% | 7.2% | 10.5% | 12.5% |
| EPS | $-2.05 | $4.20 | $-0.80 | $1.10 | $2.40 | $3.80 |
| Diluted shares | — | 65M | 65M | 65M | 65M | 66M |
| Net debt | — | $100.00M | $350.00M | $850.00M | $1.60B | $2.60B |
| P/S multiple | — | 50.0x | 40.0x | 30.0x | 25.0x | 18.0x |
| Implied price (base) | — | $153.17 | $302.51 | $446.98 | $548.29 | $508.08 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $2.0B | $2.0B | $2.0B |
| P/S multiple | 30.0x | 18.0x | 96.0x |
| Diluted shares | 66M | 66M | 66M |
| Net debt | $2.60B | $2.60B | $2.60B |
| Implied P/E † | 230x | 134x | 758x |
| 2030 Price | $873.16 | $508.08 | $2,881.12 |
| NPV @ 15% | $460.28 | $267.83 | $1,518.75 |
† Implied P/E: Multiples remain elevated across all three scenarios because PTGX is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $508.08 base case
PTGX catalysts and risks
Growth catalysts
+ FDA decision on rusfertide for polycythemia vera (Takeda partnership) — high-probability approval expected 2026
+ Commercial ramp of ICOTYDE (icotrokinra) approved March 2026 for moderate-to-severe plaque psoriasis — potential peak sales $400M-$600M
+ Clinical proof of concept for three wholly-owned assets by early 2027 (per Wolfe Research); potential de-risk of pipeline
+ Milestone payments from Takeda and J&J collaborations tied to development/regulatory events through 2027-2028
+ Ulcerative colitis and additional dermatology indications for icotrokinra — label expansion opportunity
Key risks
- Heavy reliance on milestone and royalty revenue from partners (Takeda, J&J); loss of partnership or missed regulatory milestones would materially reduce cash inflow
- ICOTYDE commercial adoption highly uncertain — psoriasis treatment market crowded; J&J Stelara competitor, Alumis competitor; peak sales may underperform $400M+ consensus
- Wholly-owned pipeline unproven; three POC readouts (early 2027) carry high binary risk; failure could impair long-term growth trajectory
- High insider selling (CEO + director sold ~$13.5M in May 2026) signals potential valuation concerns at current $103 price; stock up 120% YoY
- Biotech sector valuation compression; clinical-stage binary risks endemic to category; profit margin currently negative (-154.9%)
Methodology · Protagonist Therapeutics Inc 2030 stock forecast model
Protagonist Therapeutics Inc 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 16 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (2% cumulative for PTGX by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($2.60B by 2030) |
| 3. Time value | NPV calculated using 15% WACC (CAPM: beta 1.882) |
| 4. Multiple framework | P/S compresses with scale: bear 30.0x / base 18.0x / bull 96.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 21, 2026.
PTGX price target FAQ
What is the PTGX price target for 2030?
WallStSmart's Protagonist Therapeutics Inc 2030 base case is $508.08 per share, with a bull case of $2,881.12 and bear case of $873.16. The NPV of the base case discounted to today at 15% WACC is $267.83.
How is the Protagonist Therapeutics Inc 2030 stock forecast calculated?
The PTGX 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the PTGX price target account for dilution?
Protagonist Therapeutics Inc is projected to grow diluted share count from 64M to 66M by 2030 (a 2% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 2%.
What is the analyst consensus on PTGX stock?
16 analysts cover PTGX with an average 12-month price target of $115.21. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.